YOUR SEARCH FOR Text 110 RESULTS
11 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… increasingly diversified portfolio, driven by double-digit growth in patient demand for Jakafi … for Minjuvi in combination with lenalidomide, followed by Minjuvi monotherapy, for the …
12 of Total
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with
Press Release View all news Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
13 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… with four launches, four pivotal study readouts, at least three Phase 3 study initiations and seven proof of concept study readouts Conference Call and Webcast Scheduled …
14 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… benefit across multiple organs were observed at doses being assessed in the pivotal AGAVE-201 … positive Phase 2 results, a Phase 3 randomized trial evaluating the efficacy and safety …
15 of Total
Incyte.com Cookie Policy
… websites work the way you expect them to. We do this through the use of cookies placed on the … Incyte may use Google Analytics, in a way that does not identify you, to measure and evaluate …
16 of Total
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults wi
Press Release View all news Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
17 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… refractory B-cell malignancies: PoC with lenalidomide and plamotamab 2 parsaclisib (PI3Kδ) … cancer (SCAC): Phase 3 (POD1UM‑303) MSI-high endometrial cancer: Phase 2 (POD1UM‑101, …
18 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… atopic dermatitis and several key data readouts including CDK2i, retifanlimab, … antitumor activity across a range of doses and regimens, notably in patients with …
19 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Company’s clinical development portfolio. "Our double-digit revenue growth during the quarter … cancer (NSCLC): Phase 3 (POD1UM-304) MSI-high endometrial cancer: Phase 2 (POD1UM-101, …
20 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… the quarter was offset by an inventory drawdown for Jakafi and the typical first quarter … cancer (NSCLC): Phase 3 (POD1UM-304) MSI-high endometrial cancer: Phase 2 (POD1UM-101, …